155 related articles for article (PubMed ID: 21892101)
21. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
23. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Argiris A; Ghebremichael M; Gilbert J; Lee JW; Sachidanandam K; Kolesar JM; Burtness B; Forastiere AA
J Clin Oncol; 2013 Apr; 31(11):1405-14. PubMed ID: 23460714
[TBL] [Abstract][Full Text] [Related]
24. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Levy B; Spira A; Becker D; Evans T; Schnadig I; Camidge DR; Bauman JE; Hausman D; Walker L; Nemunaitis J; Rudin CM; Halmos B; Bowles DW
J Thorac Oncol; 2014 Jul; 9(7):1031-1035. PubMed ID: 24926548
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Guigay J; Fayette J; Dillies AF; Sire C; Kerger JN; Tennevet I; Machiels JP; Zanetta S; Pointreau Y; Bozec Le Moal L; Henry S; Schilf A; Bourhis J
Ann Oncol; 2015 Sep; 26(9):1941-1947. PubMed ID: 26109631
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.
Polite BN; Desai AA; Manchen B; Stadler WM
Clin Genitourin Cancer; 2006 Mar; 4(4):275-80. PubMed ID: 16729911
[TBL] [Abstract][Full Text] [Related]
27. The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics.
Wietrzyk J; Milczarek M; Kutner A
Oncol Res; 2007; 16(11):517-25. PubMed ID: 18306931
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.
Karampeazis A; Vamvakas L; Kotsakis A; Christophyllakis C; Kentepozidis N; Chandrinos V; Agelidou A; Polyzos A; Tsiafaki X; Hatzidaki D; Georgoulias V
J Geriatr Oncol; 2017 Jan; 8(1):23-30. PubMed ID: 27264267
[TBL] [Abstract][Full Text] [Related]
29. [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
Ohlmann CH; Markert E; Gerharz M; Pfister D; Dienes HP; Engelmann U; Heidenreich A
Urologe A; 2008 Sep; 47(9):1218-23. PubMed ID: 18679646
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
31. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
[TBL] [Abstract][Full Text] [Related]
32. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
33. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
Saraiya B; Chugh R; Karantza V; Mehnert J; Moss RA; Savkina N; Stein MN; Baker LH; Chenevert T; Poplin EA
Invest New Drugs; 2012 Feb; 30(1):258-65. PubMed ID: 20697775
[TBL] [Abstract][Full Text] [Related]
35. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer.
Mathew P; Fidler IJ; Logothetis CJ
Semin Oncol; 2004 Apr; 31(2 Suppl 6):24-9. PubMed ID: 15176001
[TBL] [Abstract][Full Text] [Related]
36. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Aulino J; Muldowney NJ; Hatakeyama H; Baumann J; Burkey B; Netterville J; Sinard R; Yarbrough WG; Cmelak AJ; Slebos RJ; Shyr Y; Parker J; Gilbert J; Murphy BA
Ann Oncol; 2010 Apr; 21(4):864-870. PubMed ID: 19850643
[TBL] [Abstract][Full Text] [Related]
37. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
38. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Mathew P; Thall PF; Bucana CD; Oh WK; Morris MJ; Jones DM; Johnson MM; Wen S; Pagliaro LC; Tannir NM; Tu SM; Meluch AA; Smith L; Cohen L; Kim SJ; Troncoso P; Fidler IJ; Logothetis CJ
Clin Cancer Res; 2007 Oct; 13(19):5816-24. PubMed ID: 17908974
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
